Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Gotlib

Showing results (31-40 of 246) with videos related to

Pageof 25
Sort By:
Hematology. American Society of Hematology. Education Program|December 4, 2018
The new tool "<i>KIT</i>" in advanced systemic mastocytosisWilliam Shomali, Jason Gotlib
Seminars in Cancer Biology|February 6, 2004
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylateSteven Coutré, Jason Gotlib
International Journal of Molecular Sciences|April 3, 2021
Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT InhibitorsWilliam Shomali, Jason Gotlib
Blood|March 3, 2018
Myelophthisic marrow involved by breast cancer and acute myeloid leukemiaWilliam Shomali, Jason Gotlib
Expert Review of Hematology|November 19, 2010
JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasmsStephen T Oh, Jason Gotlib
American Journal of Hematology|August 25, 2006
A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significanceJon S Fukumoto, Jason Gotlib
Current Hematologic Malignancy Reports|August 30, 2018
Clinical Validation of KIT Inhibition in Advanced Systemic MastocytosisJohn H Baird, Jason Gotlib
Current Hematologic Malignancy Reports|April 29, 2010
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?Stephen T Oh, Jason Gotlib
Blood|March 15, 2014
Two faces of ET: CALR and JAK2Mark P Chao, Jason Gotlib
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Insights into the molecular genetics of myeloproliferative neoplasmsHuong Marie Nguyen, Jason Gotlib
Pageof 25

Showing results (31-40 of 246) with videos related to

Sort By:
Pageof 25
Hematology. American Society of Hematology. Education Program|December 4, 2018
The new tool "<i>KIT</i>" in advanced systemic mastocytosisWilliam Shomali, Jason Gotlib
Seminars in Cancer Biology|February 6, 2004
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylateSteven Coutré, Jason Gotlib
International Journal of Molecular Sciences|April 3, 2021
Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT InhibitorsWilliam Shomali, Jason Gotlib
Blood|March 3, 2018
Myelophthisic marrow involved by breast cancer and acute myeloid leukemiaWilliam Shomali, Jason Gotlib
Expert Review of Hematology|November 19, 2010
JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasmsStephen T Oh, Jason Gotlib
American Journal of Hematology|August 25, 2006
A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significanceJon S Fukumoto, Jason Gotlib
Current Hematologic Malignancy Reports|August 30, 2018
Clinical Validation of KIT Inhibition in Advanced Systemic MastocytosisJohn H Baird, Jason Gotlib
Current Hematologic Malignancy Reports|April 29, 2010
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?Stephen T Oh, Jason Gotlib
Blood|March 15, 2014
Two faces of ET: CALR and JAK2Mark P Chao, Jason Gotlib
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Insights into the molecular genetics of myeloproliferative neoplasmsHuong Marie Nguyen, Jason Gotlib
Pageof 25